Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RGX202 |
Trade Name | |
Synonyms | RGX-202-01|RGX-202|RGX 202|Ompenaclid |
Drug Descriptions |
RGX202 is an SLC6A8 inhibitor that blocks the uptake of phosphocreatine, thereby potentially reducing ATP synthesis and resulting in the inhibition of tumor growth and metastasis (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3504-3504). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C153354 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202 | Bevacizumab Fluorouracil Irinotecan Leucovorin RGX202 | 0 | 1 |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202 | Bevacizumab Fluorouracil Leucovorin Oxaliplatin RGX202 | 0 | 1 |
Fluorouracil + Irinotecan + Leucovorin + RGX202 | Fluorouracil Irinotecan Leucovorin RGX202 | 0 | 1 |
RGX202 | RGX202 | 0 | 1 |